FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,509 | -54.7% | 22,410 | +1.6% | 0.00% | -100.0% |
Q2 2023 | $104,991 | -18.2% | 22,057 | -2.1% | 0.00% | 0.0% |
Q1 2023 | $128,387 | -41.9% | 22,524 | +2.9% | 0.00% | -50.0% |
Q4 2022 | $220,941 | -53.1% | 21,897 | +4.2% | 0.00% | -60.0% |
Q3 2022 | $471,000 | -9.1% | 21,007 | +0.5% | 0.01% | 0.0% |
Q2 2022 | $518,000 | -35.3% | 20,906 | +1.2% | 0.01% | -16.7% |
Q1 2022 | $801,000 | -33.2% | 20,651 | +0.8% | 0.01% | -33.3% |
Q4 2021 | $1,199,000 | -1.3% | 20,495 | +0.0% | 0.01% | -10.0% |
Q3 2021 | $1,215,000 | -31.4% | 20,492 | +0.5% | 0.01% | -28.6% |
Q2 2021 | $1,770,000 | +5.7% | 20,394 | +0.4% | 0.01% | -6.7% |
Q1 2021 | $1,675,000 | -8.6% | 20,317 | +0.8% | 0.02% | -11.8% |
Q4 2020 | $1,832,000 | +144.3% | 20,148 | +7.4% | 0.02% | +142.9% |
Q3 2020 | $750,000 | +60.3% | 18,753 | +37.4% | 0.01% | 0.0% |
Q2 2020 | $468,000 | +48.6% | 13,649 | -3.9% | 0.01% | +40.0% |
Q1 2020 | $315,000 | – | 14,197 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |